Saudi Arabia Pharmaceuticals and Healthcare Report Q4 2010
Business Monitor International, September 2010, Pages: 93
The Saudi Arabia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Saudi Arabia's pharmaceuticals and healthcare industry.
In BMI’s updated Business Environment Ratings (BER) for Q410, Saudi Arabia is ranked fourth out of the 19 Middle East and African markets surveyed, having dropped a place in relation to the previous quarter. Globally, it ranks 38th of the 83 countries surveyed by BMI. Saudi Arabia’s score is largely supported by the country’s wealth – and thus its preference for branded drugs – and a sizeable population, which is expected to exceed 30mn by 2014 (up from some 27mn presently).
The value of Saudi Arabia’s pharmaceutical market, calculated to be worth SAR10.39bn (US$2.77bn) at consumer prices in 2009, is forecast to post a compound annual growth rate (CAGR) of 6.52% through to 2014, when the market will reach a value of SAR14.25bn (US$3.80bn). Annual growth rates over the subsequent five years are expected to decrease under the negative influences of patent expirations, pricing controls and the increased focus on the use of generics and domestically-produced medicines, producing a cumulative 2009-2019 CAGR of 4.65%. Drivers of pharmaceutical volumes will be an increasing and ageing population, as well as the rising prevalence of major ‘civilisation’ diseases such as diabetes and cardiovascular problems, which require long-term treatment. For example, in order to address alarming rates of obesity, the Ministry of Health banned the sale of soft drinks within the hospital sector in June 2010, with the decision closely following a ban on the sale of fizzy soft drinks in schools.
The state is, however, looking to shift some of its financial responsibility for healthcare onto the private sector, mandating private health insurance coverage for expatriates, for example. This process is expected to accelerate in the coming years, although the authorities will also be seeking to encourage investment in the local pharmaceuticals industry, with the aim of boosting domestic production. Nevertheless, given that the Saudi Arabian economy is expected to perform well in the coming years, state investment into healthcare infrastructure will continue, thus working to boost the volumes of services and products used. Foreign players also remain highly interested in the promising Saudi Arabian healthcare sector, with an American delegation recently visiting to discuss investment opportunities.
However, the rapidly expanding population represents a challenge, not only from a medical provision point of view. The United Nations (UN) estimates that around half of the Saudi population is aged 25 years old or younger, which poses a substantial risk in terms of the government's ability to provide jobs and housing as well as maintain living standards. Therefore, the presence of this generation of underemployed young men, who have become accustomed to having most of their needs met by the government, could be politically explosive going forward. Although Saudi Arabia has embarked upon a China-style path of economic reform without political reform, the lack of democracy also continues to stand in the way of economic development.
Executive Summary
SWOT Analysis
Saudi Arabia Pharmaceuticals And Healthcare SWOT
Saudi Arabia Political SWOT
Saudi Arabia Economic SWOT
Saudi Arabia Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Middle East And Africa – Regional Pharmaceutical Business Environment Ratings, Q410
Rewards
Risks
Saudi Arabia – Market Summary
Regulatory Regime
Recent Regulatory Developments
Regional Regulatory Developments
Free Trade Agreements
Intellectual Property Developments
IP Deficiencies
Counterfeit Drugs
OTC Drug Market
Pricing and Reimbursement Issues
Pricing System Reform
Price Cuts
Tendering Procedures
Industry Trends and Developments
Epidemiology
Bird and Swine Influenza
HIV/AIDS
Recent Public Health Developments
Healthcare Sector
Healthcare Professionals
Primary Healthcare Provision
Secondary Healthcare Provision
Recent Healthcare Provision Developments
Health Insurance
Recent Health Insurance Developments
Pharmaceutical Distribution Sector
Table: Saudi Arabian Drug Distribution Firms
Research and Development
Medical Device Sector
Recent Medical Devices Developments
Industry Forecast Scenario
Pharmaceutical Market Forecast
Key Growth Factors – Industry
Key Growth Factors – Macroeconomic
Table: Saudi Arabia - Economic Activity, 2007-2014
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Medical Device Market Forecast
Pharmaceutical Trade Forecast
Other Healthcare Data Forecasts
Key Risks to BMI Forecasts
Competitive Landscape
Pharmaceutical Industry
Table: Saudi Arabia – Leading Pharmaceutical Companies by Sales
Foreign Industry
Domestic Industry
Recent Pharmaceutical Company Developments
Company Profiles
Indigenous Company Profiles
Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO)
Saudi Arabian Japanese Pharmaceutical (SAJA)
TABUK Pharmaceutical Manufacturing
Al Jazeera Pharmaceutical Industries (JPI)
Multinational Company Profiles
GlaxoSmithKline
Novartis
Merck & Co
Pfizer
Sanofi-Aventis
Country Snapshot: Saudi Arabia Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education and Healthcare
Table: Education, 2003-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market and Spending Power
Table: Employment Indicators, 1999-2006
Table: Consumer Expenditure, 2000-2012 (US$)
BMI Methodology
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceuticals Business Environment Ratings
Risk/Reward Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Forecast Tables
- Saudi Pharmaceutical Industries & Medical Appliances Corp (SPIMACO)
- Saudi Arabian Japanese Pharmaceutical (SAJA)
- TABUK Pharmaceutical Manufacturing
- Al Jazeera Pharmaceutical Industries (JPI)
- GlaxoSmithKline
- Novartis
- Merck & Co
- Pfizer
- Sanofi-Aventis
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
